海翔药业：股票交易异常波动，连续3个交易日收盘涨幅偏离值累计超20%，经核查无应披露未披露重大事项

Group 1 - The company, Haixiang Pharmaceutical, announced a stock price fluctuation, with a cumulative increase of over 20% in closing prices over three consecutive trading days on February 6, 9, and 10, 2026 [1] - The company confirmed that there is no need to correct or supplement previously disclosed information, and its operational status remains normal without significant changes in the internal or external environment [1] - The controlling shareholder and actual controller have not engaged in any undisclosed significant matters or traded the company's stock during the fluctuation period [1] Group 2 - As of February 10, 2026, the company has repurchased a total of 14,315,300 shares, accounting for 0.8844% of the total share capital, with a total transaction amount of 88,881,298.38 yuan [1] - The partnership firm has converted its unlisted shares of Fuhong Hanlin into H-shares, which were listed on the Hong Kong Stock Exchange on February 4, 2026 [1] - There are no revisions to the earnings forecast for the fiscal year 2025 [1]